GlassScriptPhysician profile
Nilay A Shah
NPI 1356541445
$227,817.73
in general payments reported to CMS, 2019-2025
14 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $27K · 2021: $34K · 2022: $72K · 2023: $50K · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Travel and Lodging: $5,869 · Consulting Fee: $2,376 · Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,639.75 |
| Travel and Lodging | $5,868.87 |
| Consulting Fee | $2,376.00 |
| Food and Beverage | $553.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $131,876.32 | 2019-2023 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $58,515.25 | 2022-2023 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $13,413.85 | 2019-2021 | |
| Amgen INC. | $9,875.31 | 2019-2021 | |
| Celgene Corporation | $9,076.42 | 2020-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $2,600.00 | 2019-2020 | |
| Janssen Biotech, INC. | $1,950.00 | 2019-2020 | |
| National Marrow Donor Program | $319.12 | 2022 | |
| Autolus INC | $162.82 | 2025 | |
| Allergan, INC. | $15.00 | 2022 | |
| Novo Nordisk INC | $13.64 | 2023 | Wegovy |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nilay Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.